Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seltorexant Adjunctive Therapy in MDD
NCT03227224Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of seltorexant in major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Started Aug 2017; status: completed.
02
Drugs
seltorexant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03227224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03227224.